WO2006048777A3 - Modified growth hormones - Google Patents
Modified growth hormones Download PDFInfo
- Publication number
- WO2006048777A3 WO2006048777A3 PCT/IB2005/003662 IB2005003662W WO2006048777A3 WO 2006048777 A3 WO2006048777 A3 WO 2006048777A3 IB 2005003662 W IB2005003662 W IB 2005003662W WO 2006048777 A3 WO2006048777 A3 WO 2006048777A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modified growth
- growth hormones
- growth hormone
- hormone polypeptides
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005300257A AU2005300257A1 (en) | 2004-11-04 | 2005-11-04 | Modified growth hormones |
JP2007539656A JP5017119B2 (en) | 2004-11-04 | 2005-11-04 | Modified growth hormone |
CN2005800454376A CN101094865B (en) | 2004-11-04 | 2005-11-04 | Modified growth hormones |
CA002586389A CA2586389A1 (en) | 2004-11-04 | 2005-11-04 | Modified growth hormones |
RU2007120182/13A RU2007120182A (en) | 2004-11-04 | 2005-11-04 | MODIFIED GROWTH HORMONES |
EP05807713A EP1807449A2 (en) | 2004-11-04 | 2005-11-04 | Modified growth hormones |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62565204P | 2004-11-04 | 2004-11-04 | |
US60/625,652 | 2004-11-04 | ||
US70669705P | 2005-08-08 | 2005-08-08 | |
US60/706,697 | 2005-08-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006048777A2 WO2006048777A2 (en) | 2006-05-11 |
WO2006048777A3 true WO2006048777A3 (en) | 2006-09-28 |
Family
ID=35965980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/003662 WO2006048777A2 (en) | 2004-11-04 | 2005-11-04 | Modified growth hormones |
Country Status (9)
Country | Link |
---|---|
US (3) | US7998930B2 (en) |
EP (3) | EP1807449A2 (en) |
JP (2) | JP5017119B2 (en) |
KR (1) | KR100994610B1 (en) |
CN (1) | CN101094865B (en) |
AU (1) | AU2005300257A1 (en) |
CA (1) | CA2586389A1 (en) |
RU (1) | RU2007120182A (en) |
WO (1) | WO2006048777A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7884073B2 (en) | 2004-11-04 | 2011-02-08 | Hanall Biopharma Co., Ltd. | Modified growth hormone |
US8052964B2 (en) | 2002-09-09 | 2011-11-08 | Hanall Biopharma Co., Ltd. | Interferon-β mutants with increased anti-proliferative activity |
US8252743B2 (en) | 2006-11-28 | 2012-08-28 | Hanall Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2808804B1 (en) * | 2000-05-09 | 2002-08-02 | Nautilus Biotech | METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20060251619A1 (en) * | 2005-05-04 | 2006-11-09 | Gilles Borrelly | Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides |
US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
WO2007149406A2 (en) * | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
ES2430067T3 (en) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Sewn polypeptides |
KR100944034B1 (en) | 2007-04-19 | 2010-02-24 | 한올제약주식회사 | Oral dosage formulations of protease-resistant polypeptides |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
WO2009144755A1 (en) | 2008-05-29 | 2009-12-03 | Alma Mater Studiorum - Universita' Di Bologna | Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof |
CN101343624B (en) * | 2008-06-25 | 2014-05-21 | 浙江中奇生物药业股份有限公司 | Recombined human growth hormone gene bacilliform virus, preparation and application thereof |
RU2519051C2 (en) * | 2008-06-25 | 2014-06-10 | Брааш Биотех Ллк | Compositions and methods for improving somatostatin immunogenicity in treating growth hormone and insulin-like growth factor deficiency |
DK2303314T3 (en) * | 2008-06-25 | 2014-01-13 | Braasch Biotech Llc | CHLORAMPHENICOL ACETYL TRANSFERASE (CAT) DEFECT SOMATOSTATIN FUSION PROTEIN AND USES FOR Cattle |
KR20110039348A (en) * | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Conjugated proteins with prolonged in vivo efficacy |
EP4219547A3 (en) | 2008-09-15 | 2023-10-18 | uniQure biopharma B.V. | Factor ix polypeptide mutant, its uses and a method for its production |
IT1392551B1 (en) | 2008-11-25 | 2012-03-09 | Bioindustry Park Del Canavese S P A | BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS |
IT1392567B1 (en) | 2008-12-24 | 2012-03-09 | Bioindustry Park Del Canavese S P A | USE OF A PEPTIDE DERIVED FROM ER-ALPHA FOR THE RESTORATION OF SENSITIVITY TO ANTIESTROGENIC COMPOUNDS IN MAMMARY TUMOR CELLS |
CA2747825A1 (en) | 2009-01-22 | 2010-07-29 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
CN102612376A (en) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | Growth hormones with prolonged in-vivo efficacy |
CN107056929A (en) * | 2009-12-21 | 2017-08-18 | Ambrx 公司 | Porcine somatotropin polypeptide and its purposes by modification |
NZ600361A (en) * | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
JP5980689B2 (en) * | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Stable growth hormone compound |
RU2605627C2 (en) | 2010-01-22 | 2016-12-27 | Ново Нордиск Хелс Кеа Аг | Growth hormones with prolonged efficacy in vivo |
JP2013533264A (en) | 2010-07-22 | 2013-08-22 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Growth hormone conjugate |
KR20170058446A (en) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
BR112013012228B1 (en) | 2010-11-16 | 2023-02-28 | University Of Southern California | COSMETIC METHOD FOR TREATMENT OF A SKIN CONDITION AND USES OF A SMALL MOLECULE CBP/CATENIN ANTAGONIST COMPOUND |
WO2013052162A1 (en) | 2011-10-07 | 2013-04-11 | University Of Southern California | Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells |
TW201806968A (en) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | Peptidomimetic macrocycles |
CN103987402B (en) * | 2011-12-09 | 2019-06-18 | 麦特保利药业有限公司 | The purposes of growth hormone fragment |
AU2013221433B2 (en) | 2012-02-15 | 2018-01-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
AU2013221432B2 (en) | 2012-02-15 | 2018-01-18 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US20140087964A1 (en) * | 2012-09-24 | 2014-03-27 | University Of Virginia Patent Foundation | Compositions and methods for detecting aberrant regulation, expression, and levels of hgh |
MX2015005244A (en) | 2012-11-01 | 2015-07-14 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof. |
WO2014139994A1 (en) * | 2013-03-11 | 2014-09-18 | Novo Nordisk Health Care Ag | Growth hormone compounds |
CN105229035A (en) * | 2013-03-11 | 2016-01-06 | 诺和诺德保健股份有限公司 | Growth hormone compound |
CN105120887A (en) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | Growth hormone compound formulation |
PT3139965T (en) | 2014-05-07 | 2021-12-27 | Applied Molecular Transp Llc | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
WO2016029013A2 (en) | 2014-08-21 | 2016-02-25 | Braasch Biotech Llc | Methods for improving immunological response in vaccinated animals |
CN112245565A (en) | 2014-09-24 | 2021-01-22 | 艾瑞朗医疗公司 | Peptidomimetic macrocycles and uses thereof |
CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
ES2784603T3 (en) | 2015-06-02 | 2020-09-29 | Novo Nordisk As | Insulins with recombinant polar extensions |
CA3183289A1 (en) | 2015-09-08 | 2017-03-16 | Jcr Pharmaceuticals Co., Ltd. | Novel human serum albumin mutant |
MA43348A (en) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | PROTEIN CONJUGATES |
EP3431508A4 (en) | 2016-03-14 | 2019-08-14 | JCR Pharmaceuticals Co., Ltd. | Serum albumin-20 k growth hormone fusion protein |
EP3606560A2 (en) | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
CN114599665A (en) | 2019-08-16 | 2022-06-07 | 应用分子转运公司 | Compositions, formulations and interleukin production and purification |
CN114555646A (en) | 2019-10-17 | 2022-05-27 | Jcr制药股份有限公司 | Method for producing fusion protein of serum albumin and growth hormone |
CN114728043A (en) | 2019-10-30 | 2022-07-08 | Jcr制药股份有限公司 | Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004022747A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2224901A (en) | 1937-07-20 | 1940-12-17 | Radio Kelth Orpheum Corp | Camera dolly |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4363877B1 (en) | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
US5221619A (en) | 1977-11-08 | 1993-06-22 | Genentech, Inc. | Method and means for microbial polypeptide expression |
US4898830A (en) | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
US4665160A (en) | 1982-03-22 | 1987-05-12 | Genentech, Inc. | Novel human growth hormone like protein HGH-V encoded in the human genome |
US4670393A (en) | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5618697A (en) | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
US4859600A (en) | 1983-04-25 | 1989-08-22 | Genentech, Inc. | Recombinant procaryotic cell containing correctly processed human growth hormone |
US4755465A (en) | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
US5670371A (en) | 1983-07-15 | 1997-09-23 | Bio-Technology General Corp. | Bacterial expression of superoxide dismutase |
US5198361A (en) | 1983-07-15 | 1993-03-30 | Bio-Technology General Corp. | Plasmids for production of met-asp-gln bovine growth hormone, hosts containing the plasmids, products manufactured thereby and related methods |
BG49718A3 (en) | 1983-07-15 | 1992-01-15 | Bio Technology General Corp | Method for preparing of polypeptid with superoxiddismutasne activitty |
US5637495A (en) | 1983-07-15 | 1997-06-10 | Bio-Technology General Corp. | Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods |
US5256546A (en) | 1983-07-15 | 1993-10-26 | Bio-Technology General Corp. | Bacterial expression of porcine growth hormone |
US4747825A (en) | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
US5631227A (en) | 1985-09-18 | 1997-05-20 | The Upjohn Company | Somatotropin analogs |
IL77186A0 (en) | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
EP0240224A3 (en) | 1986-03-31 | 1989-02-01 | Interferon Sciences, Inc. | An alpha interferon analogue |
US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5698418A (en) | 1988-02-17 | 1997-12-16 | Pharmacia & Upjohn Company | Fermentation media and methods for controlling norleucine in polypeptides |
US5068317A (en) | 1988-03-15 | 1991-11-26 | Eli Lilly And Company | Novel derivative of human growth hormone |
US5445826A (en) | 1988-06-28 | 1995-08-29 | Cibus Pharmaceutical, Inc. | Delivery system containing a gel-forming dietary fiber and a drug |
CA1333777C (en) | 1988-07-01 | 1995-01-03 | Randy M. Berka | Aspartic proteinase deficient filamentous fungi |
US5079345A (en) | 1988-08-19 | 1992-01-07 | Eli Lilly And Company | Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism |
EP0355460B1 (en) | 1988-08-24 | 2000-12-27 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization |
US5089473A (en) | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
US5130422A (en) | 1988-08-29 | 1992-07-14 | Monsanto Company | Variant somatotropin-encoding DNA |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5079230A (en) | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
US5688666A (en) | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US6780613B1 (en) * | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
WO1990004788A1 (en) | 1988-10-28 | 1990-05-03 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5033352A (en) | 1989-01-19 | 1991-07-23 | Yamaha Corporation | Electronic musical instrument with frequency modulation |
US5101018A (en) | 1989-06-12 | 1992-03-31 | International Minerals & Chemical Corp. | Method for recovering recombinant proteins |
US5663305A (en) | 1989-07-10 | 1997-09-02 | The Upjohn Company | Somatotropin analogs |
US5047511A (en) | 1989-08-28 | 1991-09-10 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US6787336B1 (en) | 1989-10-12 | 2004-09-07 | Ohio University/Edison Biotechnology Institute | DNA encoding growth hormone antagonists |
US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5958879A (en) | 1989-10-12 | 1999-09-28 | Ohio University/Edison Biotechnology Institute | Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal |
US6583115B1 (en) | 1989-10-12 | 2003-06-24 | Ohio University/Edison Biotechnology Institute | Methods for treating acromegaly and giantism with growth hormone antagonists |
US4988798A (en) | 1990-01-22 | 1991-01-29 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US5109121A (en) | 1990-01-22 | 1992-04-28 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US5951972A (en) | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
US5849694A (en) | 1990-07-16 | 1998-12-15 | Synenki; Richard M. | Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof |
US6344213B1 (en) | 1996-03-29 | 2002-02-05 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5310882A (en) | 1990-11-30 | 1994-05-10 | American Cyanamid Company | Somatotropins with alterations in the α-helix 3 region |
NZ260103A (en) | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin with alterations in the alpha-helix-1 region |
DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech Inc | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
ES2087323T3 (en) | 1991-02-19 | 1996-07-16 | Takeda Chemical Industries Ltd | METHOD FOR PRODUCING CYSTEINE-FREE PEPTIDES. |
JP3417558B2 (en) * | 1991-05-10 | 2003-06-16 | ジェネンテク,インコーポレイテッド | Choice of ligand agonists and antagonists |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
US5597709A (en) | 1994-01-27 | 1997-01-28 | Human Genome Sciences, Inc. | Human growth hormone splice variants hGHV-2(88) and hGHV-3(53) |
FR2722208B1 (en) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE |
US5854049A (en) | 1995-06-09 | 1998-12-29 | President And Fellows Of Harvard College | Plasmin-resistant streptokinase |
NZ286884A (en) | 1995-06-29 | 1997-12-19 | Mitsui Chemicals Inc | Use of 20 kd human growth hormone in hrt, increasing serum igf-1 levels and stimulating lipolysis |
DE122006000003I2 (en) * | 1995-09-21 | 2011-01-13 | Genentech Inc | VARIANTS OF HUMAN GROWTH HORMONE |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
JP2000508521A (en) | 1996-01-23 | 2000-07-11 | バイロファーマ・インコーポレイテッド | Methods for identifying RNA virus inhibitors |
CA2197408A1 (en) | 1996-02-13 | 1997-08-14 | Kazuo Chihara | Mutant human growth hormones and their uses |
CN1162600A (en) | 1996-02-13 | 1997-10-22 | 日本化学研究股份有限公司 | Mutant human growth hormones and their uses |
WO1998051323A1 (en) | 1997-05-13 | 1998-11-19 | The Regents Of The University Of California | Novel antiangiogenic peptide agents and their therapeutic and diagnostic use |
EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
DE69838647T2 (en) | 1997-09-08 | 2008-08-28 | Metabolic Pharmaceuticals Ltd., Melbourne | TREATMENT OF GRAVITY |
JPH1192499A (en) | 1997-09-22 | 1999-04-06 | Sumitomo Pharmaceut Co Ltd | Human growth hormone variant |
US6946265B1 (en) | 1999-05-12 | 2005-09-20 | Xencor, Inc. | Nucleic acids and proteins with growth hormone activity |
US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
AU1436401A (en) | 1999-10-21 | 2001-05-14 | Board Of Trustees Of The University Of Arkansas, The | RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof |
FR2802645B1 (en) | 1999-12-16 | 2002-03-08 | Meillat Roland | METHOD FOR EVALUATING THE PERFORMANCE OF A SET OF BIOLOGICAL AGENTS IN LIVE TARGET CELLS AND ITS APPLICATIONS |
FR2808804B1 (en) * | 2000-05-09 | 2002-08-02 | Nautilus Biotech | METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS |
AU2001256499B2 (en) | 2000-05-12 | 2007-07-26 | University College Cardiff Consultants Limited | Method for detecting growth hormone variations in humans, the variations and their uses |
DE60129432T2 (en) | 2000-05-16 | 2008-04-17 | Bolder Biotechnology, Inc., Louisville | PROCESS FOR THE RECYCLING OF PROTEINS WITH FREE CYSTEIN REST |
US6417237B1 (en) * | 2000-06-08 | 2002-07-09 | The Board Of Trustees Of The University Of Illinois | Macromolecular drug complexes and compositions containing the same |
JP2002031016A (en) | 2000-07-21 | 2002-01-31 | Toyota Industries Corp | Fuel injector |
AU2001281001B2 (en) * | 2000-08-04 | 2005-11-03 | Corixa Corporation | New immunoeffector compounds |
US20060183197A1 (en) | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
AU2002342653A1 (en) | 2001-05-14 | 2002-11-25 | The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health | Modified growth hormone |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
US20030129203A1 (en) | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
HUP0402334A3 (en) | 2001-09-04 | 2007-03-28 | Merck Patent Gmbh | Modified human growth hormone |
CA2403372A1 (en) | 2001-09-13 | 2003-03-13 | Intier Automotive Inc. | Second row fold and pivot seat assembly |
WO2003042226A2 (en) | 2001-11-09 | 2003-05-22 | Pharmacia & Upjohn Company | Single nucleotide polymorphisms in gh-1 |
GB0127213D0 (en) * | 2001-11-12 | 2002-01-02 | Univ Wales Medicine | Method of detecting growth hormone variations in humans the variations and their uses |
WO2003042245A2 (en) * | 2001-11-12 | 2003-05-22 | University Of Wales College Of Medicine | Growth hormone variations in humans and their uses |
GB2389115B (en) * | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
US20030224404A1 (en) | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
US20050202438A1 (en) | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
PA8588901A1 (en) | 2002-11-20 | 2005-02-04 | Pharmacia Corp | CONJUGATES OF N-TERMINAL HUMAN GROWTH HORMONE HORMONE AND PROCESS FOR PREPARATION |
US20040142870A1 (en) | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
EP1624847B1 (en) | 2003-05-09 | 2012-01-04 | BioGeneriX AG | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
KR100632985B1 (en) * | 2003-07-26 | 2006-10-11 | 메덱스젠 주식회사 | A method of improving efficacy of biological response-modifying proteins and the example muteins |
JP5743368B2 (en) * | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | O-linked glycosylation of peptides |
AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
WO2006024547A2 (en) | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
US7998930B2 (en) * | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
US20060251619A1 (en) * | 2005-05-04 | 2006-11-09 | Gilles Borrelly | Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides |
WO2007110230A2 (en) | 2006-03-27 | 2007-10-04 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
WO2007149406A2 (en) * | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
EP2120998B1 (en) * | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
US20120264686A9 (en) | 2008-05-29 | 2012-10-18 | Hanall Biopharma Co. Ltd | Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
-
2005
- 2005-11-03 US US11/267,871 patent/US7998930B2/en not_active Expired - Fee Related
- 2005-11-04 CA CA002586389A patent/CA2586389A1/en not_active Abandoned
- 2005-11-04 AU AU2005300257A patent/AU2005300257A1/en not_active Abandoned
- 2005-11-04 RU RU2007120182/13A patent/RU2007120182A/en not_active Application Discontinuation
- 2005-11-04 JP JP2007539656A patent/JP5017119B2/en not_active Expired - Fee Related
- 2005-11-04 KR KR1020077012644A patent/KR100994610B1/en active IP Right Grant
- 2005-11-04 WO PCT/IB2005/003662 patent/WO2006048777A2/en active Application Filing
- 2005-11-04 CN CN2005800454376A patent/CN101094865B/en active Active
- 2005-11-04 EP EP05807713A patent/EP1807449A2/en not_active Withdrawn
- 2005-11-04 EP EP12156083A patent/EP2476700A1/en not_active Withdrawn
- 2005-11-04 EP EP10006533.3A patent/EP2241574B1/en active Active
-
2006
- 2006-06-26 US US11/476,173 patent/US7884073B2/en not_active Expired - Fee Related
-
2010
- 2010-12-03 JP JP2010270672A patent/JP5117563B2/en not_active Expired - Fee Related
-
2011
- 2011-01-25 US US12/931,218 patent/US8222209B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004022747A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
Non-Patent Citations (2)
Title |
---|
DATABASE UniProt 27 March 2002 (2002-03-27), XP002371968, retrieved from EBI Database accession no. P58756 * |
FILIKOV ANTON V ET AL: "Computational stabilization of human growth hormone.", PROTEIN SCIENCE : A PUBLICATION OF THE PROTEIN SOCIETY. JUN 2002, vol. 11, no. 6, June 2002 (2002-06-01), pages 1452 - 1461, XP002371962, ISSN: 0961-8368 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8052964B2 (en) | 2002-09-09 | 2011-11-08 | Hanall Biopharma Co., Ltd. | Interferon-β mutants with increased anti-proliferative activity |
US8057787B2 (en) | 2002-09-09 | 2011-11-15 | Hanall Biopharma Co., Ltd. | Protease resistant modified interferon-beta polypeptides |
US8105573B2 (en) | 2002-09-09 | 2012-01-31 | Hanall Biopharma Co., Ltd. | Protease resistant modified IFN beta polypeptides and their use in treating diseases |
US8114839B2 (en) | 2002-09-09 | 2012-02-14 | Hanall Biopharma Co., Ltd. | Protease resistant modified erythropoietin polypeptides |
US7884073B2 (en) | 2004-11-04 | 2011-02-08 | Hanall Biopharma Co., Ltd. | Modified growth hormone |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
US8252743B2 (en) | 2006-11-28 | 2012-08-28 | Hanall Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
Also Published As
Publication number | Publication date |
---|---|
US20080026993A9 (en) | 2008-01-31 |
KR100994610B1 (en) | 2010-11-15 |
JP5117563B2 (en) | 2013-01-16 |
US20060247170A1 (en) | 2006-11-02 |
JP2011097944A (en) | 2011-05-19 |
US7884073B2 (en) | 2011-02-08 |
AU2005300257A1 (en) | 2006-05-11 |
CN101094865B (en) | 2012-04-25 |
EP2241574A1 (en) | 2010-10-20 |
CN101094865A (en) | 2007-12-26 |
US8222209B2 (en) | 2012-07-17 |
US20060094655A1 (en) | 2006-05-04 |
CA2586389A1 (en) | 2006-05-11 |
EP2241574B1 (en) | 2015-02-25 |
KR20070092218A (en) | 2007-09-12 |
EP2476700A1 (en) | 2012-07-18 |
US20070249532A9 (en) | 2007-10-25 |
EP1807449A2 (en) | 2007-07-18 |
WO2006048777A2 (en) | 2006-05-11 |
RU2007120182A (en) | 2008-12-10 |
JP5017119B2 (en) | 2012-09-05 |
JP2008518615A (en) | 2008-06-05 |
US20110130331A1 (en) | 2011-06-02 |
US7998930B2 (en) | 2011-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006048777A3 (en) | Modified growth hormones | |
EP1713440A4 (en) | Engineered proteins, and methods of making and using | |
WO2005103076A3 (en) | Erythropoietin protein variants | |
AU2003284891A1 (en) | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same | |
WO2007024705A3 (en) | Method of treating depression using a tnf-alpha antibody | |
GB0713656D0 (en) | Modified human growth hormone | |
WO2003104418A3 (en) | Reconstituted polypeptides | |
WO2006060743A3 (en) | Glucose-transport related genes, polypeptides, and methods of use thereof | |
EP1660638A4 (en) | Lipoparticles comprising proteins, methods of making, and using the same | |
WO2007149523A3 (en) | Hexahydro-isoalpha acid based protein kinase modulation cancer treatment | |
WO2005113592A3 (en) | Interferon-alpha polypeptides and conjugates | |
WO2003010284A3 (en) | Antisense modulation of c-reactive protein expression | |
WO2004001009A3 (en) | Apo-2 ligand/trail variants and uses thereof | |
WO2009013461A8 (en) | Growth hormone fusion proteins | |
WO2006047728A3 (en) | Bmp gene and fusion protein | |
EP1833844A4 (en) | Signal peptides, nucleic acid molecules and methods of treatment | |
AU2003252111A1 (en) | Fluorescent proteins, nucleic acids encoding them and methods for making and using them | |
AU2003278286A1 (en) | Method for producing acrylic acid from propane, in the presence of molecular oxygen | |
WO2006013462A3 (en) | Growth factors nsg28, nsg30, and nsg32 | |
EP1937717A4 (en) | Penumbra nucleic acid molecules, proteins and uses thereof | |
WO2009047474A3 (en) | Modified growth hormone polypeptides | |
AU2003267993A1 (en) | Monooxygenases, nucleic acids encoding them and methods for making and using them | |
WO2004053061A8 (en) | Methods of therapy and diagnosis using targeting of cells that express lax | |
AU2004206257A8 (en) | Human SAA3 nucleic acid molecule, protein, and methods of use for same | |
WO2004049917A3 (en) | Methods of therapy and diagnosis using targeting of cells that express ly-9 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005807713 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2586389 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007539656 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005300257 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4051/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007120182 Country of ref document: RU Ref document number: 1020077012644 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2005300257 Country of ref document: AU Date of ref document: 20051104 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005300257 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580045437.6 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005807713 Country of ref document: EP |